39 results about "Have Difficulty Swallowing" patented technology

A fast-melting pharmaceutical tablet comprises a porous, plastic substance, a water penetration enhancer and a binder. One or more drugs can be incorporated into the formulation at different stages of the process so as to afford a pharmaceutically active tablet. Methods of making the pharmaceutical tablet entail combining the porous, plastic material, the water penetration enhancing agent, and the binder so as to form highly plastic granules, which are compressed into tablets. The resulting tablets dissolve rapidly in the mouth and have good hardness with low brittleness. The tablets are particularly valuable to those who have difficulty swallowing conventional pills.

A fast-melting pharmaceutical tablet comprises a porous, plastic substance, a water penetration enhancer and a binder. One or more drugs can be incorporated into the formulation at different stages of the process so as to afford a pharmaceutically active tablet. Methods of making the pharmaceutical tablet entail combining the porous, plastic material, the water penetration enhancing agent, and the binder so as to form highly plastic granules, which are compressed into tablets. The resulting tablets dissolve rapidly in the mouth and have good hardness with low brittleness. The tablets are particularly valuable to those who have difficulty swallowing conventional pills.

The invention disclosed herein relate to an oral vaccine in which the vaccine composition and adjuvant(s) are carried on a solid fast-dispersing dosage form. The vaccines are targeted toward mucosal tissue and the adjuvant serves to ensure sufficient residence time for the vaccine composition on the mucosal tissue to facilitate its absorption thereby. The fast-dispersing oral solid vaccine dosage form of the invention is particularly useful to administer the vaccine to patients that have difficulty swallowing medications. In one embodiment, the invention provides a fast disintegrating oral solid vaccine dosage form comprising: an immunogenic amount of an antigenic preparation, the antigenic preparation comprising a microsphere-antigen complex; an adjuvant, wherein the adjuvant enhances the absorption of the antigen or potentiates the immunogenic response; a mucoadhesive substance; and a low density dosage form matrix.

The compositions of the present invention comprise a therapeutically effective amount of particles consisting of diphenhydramine or pharmaceutically acceptable salts thereof, optionally in combination with another drug such as pseudoephedrine, or phenylephrine and hydrocodone, in combination with rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol and / or a saccharide. These compositions are useful in treating the symptoms of one or more diseases or conditions in which diphenhydramine (alone or in combination with one or two other drugs) is a therapeutically effective, e.g. allergic rhinitis, sinusitis, upper respiratory tract infections, motion sickness, Parkinson's disease, insomnia, the common cold, and nighttime pain management, particularly for subjects or patients with dysphagia, and people ‘on the move’.

The invention belongs to the technical field of medicine, and relates to a lurasidone hydrochloride orally-disintegrating tablet preparation and a preparation method thereof. The orally-disintegrating tablet comprises the following components in mass percent: 5-60 percent of lurasidone hydrochloride, 25-80 percent of filling material, 5-20 percent of disintegrating agent, 0.02-0.15 percent of wetting agent, 0.2-5 percent of flavoring agent and 0.5-2 percent of lubricating agent. The invention aims to provide a lurasidone hydrochloride orally-disintegrating tablet with simple preparation process, low cost, convenience in use and quick action to the indications; and compared with the conventional preparation for oral use, the lurasidone hydrochloride orally-disintegrating tablet preparation can reduce the difficulty in swallowing, improve the compliance, is suitable for special populations such as the elderly, children, patients with difficulty in swallowing and mental patients, can be fully disintegrated within 60 s, can be disintegrated into extremely fine powder, is higher in drug dissolution rate and quick in absorption, and can improve the bioavailability of insoluble drugs, for example, lurasidone hydrochloride.

The present invention related to a method for oral administration of a solid composition comprising an acid labile proton pump inhibitor compound in the form of a multiple of enteric coating layered pellets, wherein the pellets are in admixture with one or more pharmaceutically acceptable thickeners capable of forming a viscous medium when dispersed in an aqueous carrier. Alternatively, the enteric coated pellets are in admixture with a viscous medium. The formed aqueous viscous suspension is administered through a gastric tube. The method and composition are especially aimed for treatment of patients in need of a proton pump inhibitor and having difficulties to swallow or for pediatric patients.

The present invention is a variably thickened pharmaceutical dosage form, its composition and its use for orally administering medications to patients that have difficulty swallowing other solid dosage forms such as tablets or capsules.

The invention is directed to a pharmaceutical composition of topiramate, an anticonvulsant which is useful for treating epilepsy. More specifically, the present invention provides a solid dosage formulation of topiramate intended primarily for use by pediatric patients, or for patients who have difficulty swallowing tablets. Processes for preparing the pharmaceutical composition are also described.

The invention discloses a temperature sensitive gel sustained-release oral agent with a paracetamol, and relates to the technical field of pharmaceutic preparation. A carrier in the oral agent provided by the invention convenient for feeding includes paracetamol serving as an active ingredient and xyloglucan or a mixture of xyloglucan and another polysaccharide, wherein another polysaccharide is pectin, chitosan, algal polysaccharides or gellan gum. According to the invention, a polymer three-dimensional gel net structure formed by the polysaccharide is used for establishing a sustained-release system combined with clinical pathology so as to obtain the temperature sensitive gel sustained-release oral agent with the paracetamol; the temperature range for sol-gel change is 35-37 DEG C which is close to body temperature, so the oral agent is particularly suitable for old people, infants and people who have difficulty in swallowing, and has obvious efficacy. The temperature sensitive gel sustained-release oral agent disclosed by the invention has obvious analgesic and antipyretic effects, is convenient for administration and free of toxic and side effects, and the drug action can last for a long time.

The invention relates to procaterol hydrochloride pharmaceutical granules, which have an effect of relieving asthma, and a preparation process of the granules. The procaterol hydrochloride granules belong to an orally rapidly dispersible preparation which is prepared from procaterol hydrochloride and medicinal pharmaceutical excipients, and the preparation is suitable for treating bronchial asthma, asthmatic bronchitis and chronic obstructive pulmonary disease. According to the invention, the prepared granule medicine is rapid to be dissolved and uniform to be dispersed; the medicine can be taken after being dissolved in water and the medicine can be directly taken without water as well; the medicine is delicate and sweet in taste; the medicine is capable of effectively overcoming medication rejecting psychology of patients and meeting a medication requirement during an asthma acute attacking period, and the medicine is especially suitable for children, old people or patients having difficulty in swallowing. Upon detection, the procaterol hydrochloride granules prepared by the invention are quite excellent in static dissolubility, and are obviously better than a preparation of a conventional process in content uniformity; and the procaterol hydrochloride granules effectively guarantee the timeliness, the safety and the effectiveness of clinical treatment, and the procaterol hydrochloride granules are quite high in value of popularization.

The invention is directed to a pharmaceutical composition of topiramate, an anticonvulsant which is useful for treating epilepsy. More specifically, the present invention provides a solid dosage formulation of topiramate intended primarily for use by pediatric patients, or for patients who have difficulty swallowing tablets. Processes for preparing the pharmaceutical composition are also described.

The invention relates to pyridostigmine bromide odor masking orally disintegrating tablets and a preparation method thereof. The tablets belong to orally disintegrating tablets, and the orally disintegrating tablets consist of pyridostigmine bromide, an odor masking agent, a filling agent, a disintegrating agent and a flavoring agent basically, can be prepared by a direct tablet compressing process or a wet granulation process, have good mouthfeel and are disintegrated for 20 to 45 seconds; and in the dissolution detection process, the average cumulative dissolution quantity in 0.1mol / L of hydrochloric acid medium within 5 minutes is more than 85 percent. The tablets have good mouthfeel and quick response, are quickly disintegrated and convenient to take, and are particularly suitable to be taken by the old, children and patients who suffer from dysphagia and are in special environments (such as an environment in which water is difficult to take). The preparation method does not have special requirements on equipment, and products have controllable quality and low cost, and are easy to produce industrially.

The present invention relates to: an ingestion-assisting oleaginous composition that is for persons having difficulty swallowing / masticating and that is obtained by rapidly cooled mixing / kneading processing of a composition having an SFC of 3-18% in the range of 5-25 DEG C and containing an oil and an emulsifier having an HLB value of 1-10; a food for persons having difficulty swallowing / masticating containing shredded or pulverized edible food and the ingestion-assisting oleaginous composition for persons having difficulty swallowing / masticating; and a method that is for producing the food for persons having difficulty swallowing / masticating and that is characterized by mixing shredded or pulverized edible food with the ingestion-assisting oleaginous composition that is for persons having difficulty swallowing / masticating and that is obtained by rapidly cooled mixing / kneading processing of a composition having an SFC of 3-18% in the range of 5-25 DEG C and containing an oil and an emulsifier having an HLB value of 1-10. As a result, it is possible to provide: an ingestion-assisting oleaginous composition for persons having difficulty swallowing / masticating that can easily produce a food that persons having difficulty swallowing / masticating can easily consume; and a food for persons having difficulty swallowing / masticating that uses same.

The invention relates to an olanzapine oral instant film which can be dissolved immediately in the oral cavity, which is used for improving the use performance of the olanzapine and belongs to the field of pharmaceutical preparations. The mouth-dissolving film includes active pharmaceutical ingredients and pharmaceutically applicable auxiliary materials, the active pharmaceutical ingredient is olanzapine, and pharmaceutically applicable auxiliary materials include: film-forming materials, plasticizers, absorption accelerators, flavoring agents and other auxiliary materials, film-forming materials Include at least gelatin. This orally dissolving film has the advantages of high drug loading, thin thickness, good taste, instant dissolution in the oral cavity without drinking water, and fast oral absorption, which solves the poor drug compliance of schizophrenic patients and the phenomenon of Tibetan medicine and vomiting. Especially suitable for patients with swallowing difficulties.

The compositions of the present invention comprise a therapeutically effective amount of particles consisting of diphenhydramine or pharmaceutically acceptable salts thereof, optionally in combination with another drug such as pseudoephedrine, or phenylephrine and hydrocodone, in combination with rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol and / or a saccharide. These compositions are useful in treating the symptoms of one or more diseases or conditions in which diphenhydramine (alone or in combination with one or two other drugs) is a therapeutically effective, e.g. allergic rhinitis, sinusitis, upper respiratory tract infections, motion sickness, Parkinson's disease, insomnia, the common cold, and nighttime pain management, particularly for subjects or patients with dysphagia, and people ‘on the move’.

A method of treating or preventing dehydration in an individual having impaired swallowing such as dysphagia can include administering to the individual having the dysphagia an effective amount of a composition containing a salivating agent and a cooling agent in a weight ratio of 1:0.06 to 1:0.2. Optionally the composition includes a tingling agent. The composition can be a powder that is reconstituted before administration, for example at the point of consumption. A thickening or thin cohesive agent can be included in the powder and / or can be included in a liquid in which the powder is reconstituted. The composition can be a beverage containing the salivating agent and the cooling agent in a total amount of at least 3.0 wt.% of the beverage, for example at least 6.0 wt.% of the beverage.The composition can be a ready-to-drink beverage or a frozen dessert on a stick.

The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and / or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with bipolar patients.

The invention described herein provides a fast dispersing oral solid dosage form containing monoamine oxidase B inhibitor (MAO-B inhibitor) as the active ingredient, and method of treating disease therewith, such as Parkinson's disease. In one embodiment, the monoamine oxidase B inhibitor selegiline or its analogue can be the sole active ingredient in the composition administered. The dosage form composition is formulated to promote absorption through the buccal, sublingual, pharyngeal and / or esophageal mucous membrane tissue, such that at least 5% of the active ingredient is absorbed within one minute of placement in the oral cavity, as determined by a buccal absorption test. Monoamine oxidase B inhibitor compounds administered in accordance with the invention decrease the amount of undesirable metabolites associated with first pass effect of selegiline, for example, such as amphetamine and methamphetamine. The invention provides a number of other advantages over conventional orally administered tablet forms, including administration of monoamine oxidase B inhibitor compounds to patients that have difficulty swallowing.

The invention discloses an American ginseng effervescent tablet containing vitamin C and a preparation method thereof. The invented product is easy to carry and can be taken by effervescence anytime and anywhere. It retains the ginseng essence of the extract. After effervescence, the fragrance of the original ginseng itself is restored. It provides convenience for people who have difficulty swallowing, without going through the process of gastrointestinal disintegration.

The present invention relates to an oil and fat composition for feeding aids for people with difficulty in swallowing and chewing. Its SFC in the range of 5 to 25°C is 3 to 18%, and it is obtained by emulsifying the oil containing oil and having an HLB value of 1 to 10 The composition obtained by quenching and kneading the composition of the preparation; the food for people with swallowing and chewing difficulties, which contains the above-mentioned oil and fat composition for feeding aids for people with swallowing and chewing difficulties and minced food that can be ingested or Pulverized product; a method for producing a food for people with swallowing and chewing difficulties, wherein the oil and fat composition for feeding aids for people with swallowing and chewing difficulties is mixed with chopped or pulverized foods that can be ingested. The oil and fat composition for feeding aids for difficult persons has an SFC of 3 to 18% in the range of 5 to 25°C, and is obtained by quenching and kneading a composition containing fat and oil and an emulsifier with an HLB value of 1 to 10 of. According to the present invention, it is possible to provide an oil and fat composition for assisting feeding for people who have difficulty swallowing and chewing, and a food for people who have difficulty swallowing and masticating using the oil and fat composition, wherein the oil and fat composition can be easily produced and swallowed, Foods that are easy to ingest for those who have difficulty chewing.

The invention disclosed herein relate to an oral vaccine in which the vaccine composition and adjuvant(s) are carried on a solid fast-dispersing dosage form. The vaccines are targeted toward mucosal tissue and the adjuvant serves to ensure sufficient residence time for the vaccine composition on the mucosal tissue to facilitate its absorption thereby. The fast-dispersing oral solid vaccine dosage form of the invention is particularly useful to administer the vaccine to patients that have difficulty swallowing medications. In one embodiment, the invention provides a fast disintegrating oral solid vaccine dosage form comprising: an immunogenic amount of an antigenic preparation, the antigenic preparation comprising a microsphere-antigen complex; an adjuvant, wherein the adjuvant enhances the absorption of the antigen or potentiates the immunogenic response; a mucoadhesive substance; and a low density dosage form matrix.

This disclosure provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units, wherein said capsule dosage form is bioequivalent to the marketed ToprolXL® tablet. The extended-release capsule dosage form comprising coated discrete units can be sprinkled onto food to ease administration to patients who have difficulty swallowing tablets or capsules.

The invention relates to the fields of medicine and food, in particular to a ginseng freeze-dried orally disintegrating tablet and a preparation method thereof. The present invention solves the rapid disintegration of tablets in the oral cavity through freeze-drying technology in ginseng medicine, food and health food. Good, suitable for people who have difficulty swallowing, such as the elderly and children, to improve medication compliance, and suitable for people with inconvenient drinking water.

A cup for a patient suffering from dysphagia comprises a base upon which the cup is capable of standing when on a level surface and a leading wall extending from the base. The leading wall has a first portion that is substantially planar or concave when viewed from outside the cup, the first portion being at an angle of at least 100 degrees relative to the base. The cup also comprises a trailing wall opposite the leading wall, wherein the trailing wall extends from the base to the lip of the cup; and side walls extending between the leading and trailing walls, the side walls being convex when viewed from outside of the cup. The lip of the cup is upwardly inclined relative to the base in the direction of the trailing wall to the leading wall. The cup allows a patient suffering from dysphagia to drink without having to unduly tip back his or her head.

The invention discloses a swallowing real-time monitoring method and system thereof. The microwave image acquisition unit acquires the microwave image of the throat of the monitored person in a state of eating and drinking in real time as a real-time monitoring image, and the main control unit performs processing according to the real-time monitoring image and reference image data. To determine whether the monitored person has dysphagia. It overcomes the technical problems of poor real-time swallowing monitoring in the existing technology, poor experience of the monitored person, and difficult access to professional inspection equipment or drugs, and realizes real-time and effective monitoring of whether the monitored person has dysphagia, thereby improving the quality of the monitored person. quality of life of the patient.

A thickener, as well as nutritional products comprising the thickener, uses thereof, methods of manufacture thereof, methods for improving cohesiveness of nutritional products, and related systems are disclosed. The nutritional product has improved cohesiveness to promote a safer and more efficient swallowing of food masses by individuals with dysphagia, such as dysphagia. In a preferred embodiment, the nutritional product comprises a thickening agent, the thickening agent comprising beta-glucan and an additive. Preferably, the nutritional product has a relaxation time of from 10 ms to 2000 ms as measured by the CaBER experiment at a temperature of 20 DEG C.

A thickening powder promotes safe swallowing of a nutritional product by an individual with dysphagia and can be used in methods of treating dysphagia, promoting safe swallowing of a nutritional product, and mitigating a risk of aspiration during swallowing of a nutritional product. The powder contains beta-glucan and at least one carrier ingredient in an amount that is neutral toward or enhances the extensional properties of the nutritional product. The at least one carrier ingredient can be one or more of maltodextrin, isomaltulose, sucrose or lactose. The powder can be diluted in a diluent to form an aqueous solution that is at least a portion of a nutritional product and to improve the cohesiveness of the nutritional product. Preferably, the resultant nutritional product has a shear viscosity greater than 200 mPas and up to about 2,000 mPas, preferably greater than 200 mPas and up to about 500 mPas, more preferably 250 mPas to about 450 mPas, most preferably 250 mPas to about 400 mPas, when measured at a shear rate of 50s-1 at a temperature of 20 DEG C.

This disclosure provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units, wherein said capsule dosage form is bioequivalent to the marketed Toprol-XL® tablet. The extended-release capsule dosage form comprising coated discrete units can be sprinkled onto food to ease administration to patients who have difficulty swallowing tablets or capsules.